In the HALT-C trial that included over 1000 HCV+ patients with moderate to severe fibrosis [30], 11% and 27% of patients with bridging fibrosis or cirrhosis had AFP values above 20 ng/mL, respectively [31]. The gene discussed is AFP; the disease is Cirrhosis.